Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
OBJECTIVE
To determine the immunohistochemical expression of ErbB2 in     adamantinomatous craniopharyngiomas (ACP) and to assess its relationship with     nuclear expression of β-catenin in surgically resected human ACP tissue     sections and to estimate whether these tumors could be candidates for anti-ErbB2     therapy.


METHODS
The ErbB2 and β-catenin immunostaining was     performed on paraffin embedded tissue sections of 20 ACP using     avidin-biotin-peroxidase complex method. ErbB2 immunoreactivity was interpreted     according to the American Society of Clinical Oncology/ College of American     Pathologists criterions for breast carcinoma.


RESULTS
Foci of nuclear     reactivity for β-catenin was observed in all ACP tissue specimens mainly     concentrated in whorl like arrays of the epithelial cells. Two (10%) of the     cases were score 3+ for ErbB2 as demonstrated by strong complete membrane     staining. However, the localization of 3+ ErbB2 cells was different from those     with nuclear β-catenin immunoreactivity.


CONCLUSIONS
Our preliminary data     demonstrate score 3+ staining for ErbB2 in 10% of ACP and different localization     of 3+ ErbB2 cells and cells with nuclear β-catenin immunoreactivity.     However, because of the small number of cases, further studies with larger     samples should be conducted to verify and validate our preliminary data and to     determine the effect of ErbB2 protein in ACP cell growth, survival and     differentiation.
Sisli Etfal Training and Research Hospital, Department of Endocrinology and Metabolism, Istanbul, Turkey. zuhur744@gmail.com
Sayid Shafi
SS
Zuhur
Canan
C
Tanik
Rumeysa Selvinaz
RS
Erol
Ahmet Murat
AM
Musluman
Fevziye
F
Kabukcuoglu
Yuksel
Y
Altuntas
D000293:Adolescent; D000328:Adult; D002454:Cell Differentiation / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D055815:Young Adult; D051176:beta Catenin / Q000378:metabolism
D018719:Erb-b2 Receptor Tyrosine Kinases; D051176:beta Catenin; C495270:CTNNB1 protein, human; C508053:ERBB2 protein, human